Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Pfizer

Status: Completed

Conditions: Hypertension

Treatments: Drug: Olmesartan medoxomil

Study type: Observational

Funder types: Industry

Identifiers

NCT00796159

A0021004

Details and patient eligibility

About

This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension

Full description

Non Probability Sampling

Enrollment: 1,723 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and Female patients 18 to 65 y/old
• Patient previously taking low-dose medoxomil or any other ARB alone with uncontrolled BP
• Patient with uncontrolled mild to moderate hypertension (SBP>= 140 and <=179 mmHg OR DBP of >=90 and <=109 mmHg)

Exclusion criteria

• Pregnant of Lactating women
• History of secondary hypertension

Trial design

1,723 participants in 1 patient group

Olmesartan medoxomil + HCTZ

Treatment:

Drug: Olmesartan medoxomil